TrialDiabetes, obesity & metabolism2021

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.

Julie Dubourg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.